Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib 18 mg versus 24 mg in radioiodine-refractory differentiated thyroid cancer
2014-005199-27Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lenvatinib in well-differentiated thyroid cancer (WDTC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Objective response rate at 24 weeks and Grade 3 or higher treatment-emergent adverse events in the first 24 weeks. Started Jan 2016; status: completed.
02
Drugs
lenvatinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2014-005199-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005199-27.